Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMAP ECMO - Beta receptor modulation trial
2024-511805-42-00Phase 2Authorised
- Sponsor
- Erasmus MC
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of esmolol in cardiogenic shock (2 arms), sponsored by Erasmus MC. Primary endpoint: Change in heart rate at 24 hours. Planned start May 2024; status: authorised.
02
Drugs
esmolol
03
Conditions
cardiogenic shock
Beyond the preview
Go deeper on 2024-511805-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511805-42-00.